Triple-negative breast cancer is a subtype characterized by the absence of hormone receptors and HER2 expression. These features influence tumor behavior and define specific treatment approaches in modern oncology. Management requires specialized oncology care and individualized treatment planning based on disease stage and patient characteristics. Access to reliable medical inform... https://www.oncoespecializados.com/medicamentos/atezolizumab-tecentriq-precio